Encouraging Results of VEGF Trap (Aflibercept) Highlighted at ASCO 2007 Annual Meeting
Sanofi-aventis Regeneron Pharmaceuticals, Inc.Salah Mahyaoui Lauren Tortorete+ 33 6 73 68 78 88 +1.212.845.5609ltortorete@biosector2.comAnne Bancillon+ 33 6 86 31 03 89Encouraging Results of VEGF Trap (Aflibercept) Highlighted at ASCO 2007 Annual Meeting-- Regeneron and sanofi-aventis to initiate a large Phase 3 programin five major tumor types in 2007 --Paris, France and Tarrytown, NY, June 2, 2007 - Sanofi-aventis (Euronext: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today encouraging preliminary results from two Phase 2 studies in